Fujifilm Diosynth Biotechnologies, a biologics CDMO and a subsidiary of Fujifilm Corporation, has selected Holly Springs, North Carolina as the location for its new JPY 200 billion ($1.9-billion) large-scale cell-culture biomanufacturing site.  

The company previously announced the new facility in the US in January 2021 but had not selected the site location. The new facility will be used to find a large-scale cell-culture manufacturing for bulk drug-substance production with 8 x 20,000-L bioreactors with the potential to expand and add a further 24 x 20,000-L bioreactors. In addition, the facility will also provide commercial-scale, automated fill-finish and assembly, packaging, and labelling services. The facility is expected to be operational by the spring of 2025.

Fujifilm Diosynth Biotechnologies also has an existing facility in Morrisville, North Carolina.

Source: Fujifilm Diosynth Technologies